Email :

Call : +91 44 2244 2124 / +91 44 2244 2127



The total economic cost of disease is 3 times the loss due to mortality because of depressed productivity and is more than 8.2% of gross value of production of a country's poultry industry.

Managing bacterial and mycoplasmal diseases is a major challenge today because pathogens often interact with not only the host (bird) and its environment, but also with one another. Mycoplasma interacts with other respiratory pathogens, respiratory viruses, Escherichia coil and cause chronic respiratory disease (CRD & CCRD).

Mycoplasma also interacts with Newcastle disease virus (NDV), Infectious Bronchitis virus (IBV) (including vaccine strains) resulting in a synergistic effect with M. gallisepticurn and M. synoviae causing more severe disease.


  • Helps in shorter therapy duration
  • Inhibits rate of bacterial growth, toxin production thereby reduces damage to birds and provides more time to the immune system
  • Improves clinical and microbiological outcomes
  • Higher recovery rate & decreases likelihood of re-infection
  • Reduces mortality
  • Prevents emergence of resistance during antibiotic therapy
  • Higher bacterial eradication and prevents further dissemination of resistant strains


  • Broad Spectrum Antibacterial
  • Rapidly bactericidal
  • Therapeutic combination with excellent synergism 
  • Bronchodilator, Mucolytic and Expectorant Once Daily Dosing
  • Excellent safety record


For the prevention, control and treatment of severe bacterial, mycoplasmal (multi-factorial) infections of poultry including Mycoplasmosis (CRD & CCRD), Infectious Coryza, Necrotic Enteritis, Colibacillosis, Salmonellosis, Fowl Cholera, etc


  • 1 ml per 10 kg bodyweight
  • To be administered continuously for a period of 3 — 5 days once daily in drinking water depending upon the severity of infection or as directed by a Registered Veterinary Practitioner.


1 Litre and 5 Litre HDPE containers